Prostate cancer, especially in advanced stages such as castration-resistant prostate cancer, is challenging to treat. Traditional therapies targeting androgen receptor (AR) signaling have limited ...
A TTUHSC research team led by Srinivas Nandana, Ph.D., (center) and Manisha Tripathi, Ph.D., (left) recently completed a study focused on uncovering the molecular and signaling mechanisms that drive ...
A poorly characterized protein, historically thought to be a chaperon or enzyme, may actually be a key player in prostate cancer. In a systematic CRISPR screen, scientists from Arc Institute, UCSF, ...
The dinuclear platinum(II) complexes inhibit prostate cancer cell growth by binding to the androgen receptor (AR) and disrupting AR-mediated gene expression. This mechanism leads to apoptosis and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results